Patients taking GLP-1 receptor agonists like tirzepatide can safely receive electroconvulsive therapy for severe depression using a modified fasting protocol, according to a 2026 case report. A patient with treatment-resistant depression completed 17 ECT sessions without complications while continuing her weight loss medication, suggesting that doctors can adjust pre-treatment fasting requirements instead of asking patients to stop these drugs.

Electroconvulsive therapy, or ECT, is a powerful treatment for severe depression that requires patients to fast before the procedure. However, patients taking GLP-1 receptor agonists, a popular class of weight loss and diabetes medications like Ozempic and Zepbound, face a unique problem: these drugs slow stomach emptying, which increases the risk of food entering the lungs during anesthesia. According to Gram Research analysis, doctors developed a new fasting protocol to keep patients safe while still allowing them to receive this life-saving treatment. A case report published in 2026 describes a patient with severe depression on tirzepatide who completed 17 ECT sessions successfully using this new approach, suggesting that careful planning can help patients benefit from ECT without stopping their weight loss medication.

Key Statistics

A 2026 case report published in The Journal of ECT documented a patient with refractory major depressive disorder on tirzepatide who successfully completed 17 electroconvulsive therapy treatments without complications using a novel pre-ECT fasting protocol.

According to research reviewed by Gram, the modified fasting protocol for patients on GLP-1 receptor agonists eliminated the need for frequent rapid sequence intubations, reducing treatment time and recovery time for each ECT session.

A case report from 2026 showed that a patient on tirzepatide, a GLP-1 receptor agonist, was able to continue her weight loss medication throughout her entire 17-session course of electroconvulsive therapy without aspiration events or other complications.

The Quick Take

  • What they studied: How to safely perform electroconvulsive therapy in patients taking GLP-1 receptor agonist medications, which are commonly used for weight loss and diabetes management.
  • Who participated: One patient with severe, treatment-resistant major depressive disorder who was taking tirzepatide, a GLP-1 receptor agonist medication.
  • Key finding: The patient completed 17 electroconvulsive therapy treatments without any complications using a specially designed fasting protocol that accounts for how GLP-1 medications slow stomach emptying.
  • What it means for you: If you take weight loss or diabetes medications like Ozempic, Zepbound, or tirzepatide and need electroconvulsive therapy for severe depression, you may not need to stop your medication. Doctors can now use a modified fasting plan to keep you safe during treatment. However, this is based on one patient’s experience, so talk with your medical team about your specific situation.

The Research Details

This is a case report, which means doctors documented the medical care and outcomes for one specific patient. The patient had severe depression that didn’t respond to standard treatments and was taking tirzepatide, a medication that slows how quickly food moves through the stomach. Electroconvulsive therapy requires general anesthesia, and doctors typically ask patients to fast for many hours before the procedure to prevent food from entering the lungs during treatment. The research team developed a new fasting protocol specifically designed for patients on GLP-1 medications, which slow stomach emptying more than usual. They then carefully monitored this patient through 17 ECT sessions using their new protocol. The case report documents what happened at each step and whether any problems occurred.

This research matters because more patients are now taking GLP-1 receptor agonists for weight loss and diabetes, but these medications create a safety challenge for anesthesia. Standard fasting instructions may not be enough to empty the stomach in patients on these drugs, increasing aspiration risk. A case report allows doctors to describe a new solution in detail before testing it in larger studies. This helps other medical teams understand how to care for this growing population of patients who need both weight loss medication and psychiatric treatment.

This is a single case report, which is the lowest level of research evidence. It shows that one patient did well with this approach, but it does not prove the method works for everyone. The findings are valuable for suggesting new ideas and helping doctors think about patient care, but larger studies with many patients would be needed to confirm safety and effectiveness. The report was published in a peer-reviewed journal, meaning other experts reviewed the work before publication. However, readers should understand that one successful case does not guarantee the same results for other patients.

What the Results Show

The patient, who had severe depression unresponsive to medications and therapy, was taking tirzepatide when she needed electroconvulsive therapy. Using the new fasting protocol developed by the ECT and anesthesia team, she completed all 17 planned ECT treatments without any complications. No aspiration events occurred, meaning food did not enter her lungs during any of the procedures. The patient was able to continue taking her tirzepatide throughout the entire course of treatment, avoiding the burden of stopping and restarting the medication. Recovery from each ECT session proceeded normally, and the patient’s depression improved as expected with the treatment course.

The case report highlights that the new fasting protocol was less burdensome than standard approaches. Instead of requiring a 24-hour clear-liquid diet every other day, the modified protocol allowed better balance between safety and patient comfort. The team also noted that avoiding frequent rapid sequence intubations, a more intensive type of airway management, reduced treatment time and recovery time for each session. These practical improvements matter because they make it easier for patients to complete their full course of ECT without stopping important medications.

Before this case report, doctors faced a dilemma when patients on GLP-1 medications needed ECT. Standard fasting protocols were designed for patients with normal stomach emptying rates. GLP-1 medications slow stomach emptying, so standard fasting might not be enough to prevent aspiration. Some doctors might have asked patients to stop their weight loss medication before ECT, but this creates problems: patients lose the benefits of the medication, and stopping and restarting can be difficult. This case report suggests a third option: modify the fasting protocol instead of stopping the medication. This approach aligns with modern thinking about keeping patients on their necessary medications whenever safely possible.

This report describes only one patient, so we cannot know if the new protocol works equally well for all patients on GLP-1 medications. Different patients may have different stomach emptying rates, different doses of medication, and different medical conditions. The patient was successful, but this does not guarantee success for others. The report does not include detailed measurements of stomach emptying or other technical data that would help doctors predict which patients might have problems. Larger studies with many patients would be needed to confirm that this protocol is safe and effective for widespread use. Additionally, this case report does not compare the new protocol to other possible approaches, so we cannot say whether it is better than alternatives.

The Bottom Line

If you take a GLP-1 receptor agonist and need electroconvulsive therapy for severe depression, discuss this case report with your psychiatrist and anesthesiologist. They may be able to develop a modified fasting protocol that allows you to continue your medication safely. Do not stop your weight loss or diabetes medication without medical guidance. Work with your medical team to create a plan tailored to your specific situation. This recommendation is based on one successful case, so ongoing communication with your doctors is essential.

This research is most relevant to patients with severe, treatment-resistant depression who are taking GLP-1 receptor agonists like semaglutide, tirzepatide, or liraglutide. It is also important for psychiatrists, anesthesiologists, and ECT specialists who care for this growing population. Patients considering ECT who worry about stopping their weight loss medication should know that alternatives may exist. This case report is less relevant to patients with depression who are not on GLP-1 medications or to patients on these medications who do not need ECT.

Electroconvulsive therapy typically involves multiple sessions over several weeks. In this case, the patient completed 17 sessions. Improvements in depression symptoms usually begin within the first few sessions, though the full benefit may take several weeks to develop. The new fasting protocol did not delay treatment or recovery, so patients should not expect longer timelines compared to standard ECT. However, individual responses vary, and your doctor can discuss realistic expectations for your situation.

Frequently Asked Questions

Can I stay on my weight loss medication if I need electroconvulsive therapy?

A 2026 case report shows one patient successfully completed 17 ECT sessions while taking tirzepatide using a modified fasting protocol. Talk with your psychiatrist and anesthesiologist about developing a personalized plan, as this is based on one patient’s experience.

What is the risk of aspiration during ECT for patients on GLP-1 medications?

GLP-1 drugs slow stomach emptying, increasing aspiration risk during anesthesia. A new fasting protocol was designed to address this. The reported patient had no aspiration events across 17 treatments, but more research is needed to confirm safety for all patients.

How long do I have to fast before electroconvulsive therapy if I take Ozempic or Zepbound?

Standard fasting protocols may not work for patients on GLP-1 medications. A 2026 case report describes a modified protocol that was less burdensome than a 24-hour clear-liquid diet every other day. Your doctor can create a personalized fasting schedule based on your medication and medical history.

Is electroconvulsive therapy safe for people taking GLP-1 receptor agonists?

One patient on tirzepatide completed 17 ECT sessions safely in 2026 using a specially designed fasting protocol. However, this is a single case report. Larger studies are needed to confirm safety for all patients on these medications.

Will I need to stop my weight loss medication before ECT?

A 2026 case report shows one patient continued tirzepatide throughout 17 ECT sessions without problems. Rather than stopping medication, doctors can modify fasting protocols. Discuss your specific situation with your medical team before making any changes.

Want to Apply This Research?

  • If using an app to track mental health during ECT, record mood, anxiety, and sleep quality daily. Also track any side effects from both ECT and your GLP-1 medication. Note the date of each ECT session and any changes in how you feel in the days following treatment. This data helps your doctor adjust your care plan.
  • Work with your medical team to establish a clear fasting schedule before each ECT session. Set app reminders for when to stop eating and drinking based on your personalized protocol. Track your adherence to the fasting schedule and report any difficulties to your doctor. Continue taking your GLP-1 medication as prescribed unless your doctor instructs otherwise.
  • Use your app to monitor mood, energy, and depression symptoms throughout your ECT course. Track any gastrointestinal symptoms or medication side effects. After completing ECT, continue monitoring your mental health to assess long-term benefits. Share this data with your psychiatrist at follow-up appointments to guide decisions about ongoing treatment.

This case report describes the experience of one patient and should not be considered medical advice for your individual situation. Electroconvulsive therapy and GLP-1 receptor agonists are serious medical treatments with potential risks and benefits. If you are considering ECT while taking a weight loss or diabetes medication, discuss this research with your psychiatrist, anesthesiologist, and primary care doctor. They can evaluate your specific medical history, current medications, and health conditions to determine the safest approach for you. Do not stop or change any medications without medical guidance. This article is for educational purposes and does not replace professional medical advice.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Navigating Electroconvulsive Therapy in Patients on GLP-1 Receptor Agonists: Balancing Safety, Compliance, and Treatment Consistency: A Case Report. , The journal of ECT (2026). PubMed 42844676 | DOI
Topics
electroconvulsive therapy ECT GLP-1 receptor agonists weight loss medication safety anesthesia fasting protocol treatment-resistant depression tirzepatide Ozempic Zepbound aspiration risk anesthesia psychiatric treatment medication management